Kestra Medical Technologies, Ltd.
KMTS Healthcare Medical Instruments & Supplies
Kestra Medical Technologies, Ltd.’s revenue for fiscal 2026 (year ended April 2026) was $95.1 million, up 59.0% from fiscal 2025. In the quarter to July 2026, revenue grew 59.9%, EPS fell 50.0%, free cash flow fell 17.8% and total debt rose 74.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow KMTS
Kestra Medical Technologies, Ltd. (KMTS) Piotroski F-score
Kestra Medical Technologies, Ltd.'s Piotroski F-score for fiscal 2026 is 4 out of 9: 4 of nine tests of profitability, leverage and efficiency passed.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2026 | 4 | — |
How fiscal 2026’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (40.24%) | (73.83%) | Fail | 0 |
| Positive operating cash flow | (81.70m) | (77.61m) | Fail | 0 |
| Rising return on assets | (40.24%) | (73.83%) | Pass | 1 |
| Cash flow above net income | 49.91m | 48.53m | Pass | 1 |
| Falling long-term leverage | 0.13 | 0.24 | Pass | 1 |
| Rising current ratio | 4.41 | 6.72 | Fail | 0 |
| No new shares issued | 54,185,000 | 24,584,000 | Fail | 0 |
| Rising gross margin | 51.37% | 40.47% | Pass | 1 |
| Rising asset turnover | 0.29 | 0.35 | Fail | 0 |
| Piotroski F-score | Mixed | 4 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| NVST Envista Holdings Corporation compare | 7 |
| AZTA Azenta, Inc. compare | 7 |
| ATRC AtriCure, Inc. compare | 7 |
| LMAT LeMaitre Vascular, Inc. compare | 6 |
| XRAY DENTSPLY SIRONA Inc. compare | 6 |
| WRBY Warby Parker Inc. compare | 6 |
| KMTS Kestra Medical Technologies, Ltd. | 4 |
| STAA STAAR Surgical Company compare | 2 |
| PLSE Pulse Biosciences, Inc compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover